Placebo + Linaclotide
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Irritable Bowel Syndrome With Constipation (IBS-C)
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Trial Timeline
Jul 1, 2013 → May 1, 2015
NCT ID
NCT01880424About Placebo + Linaclotide
Placebo + Linaclotide is a phase 3 stage product being developed by AstraZeneca for Irritable Bowel Syndrome With Constipation (IBS-C). The current trial status is completed. This product is registered under clinical trial identifier NCT01880424. Target conditions include Irritable Bowel Syndrome With Constipation (IBS-C).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01880424 | Phase 3 | Completed |
Competing Products
20 competing products in Irritable Bowel Syndrome With Constipation (IBS-C)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linaclotide + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| YM060 + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| linaclotide + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron | Astellas Pharma | Pre-clinical | 23 |
| YM060 | Astellas Pharma | Phase 2 | 52 |
| ONO-2952 + Placebo comparator | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2952 + ONO-2952 Matching Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| duloxetine | Eli Lilly | Approved | 85 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | AbbVie | Phase 3 | 77 |
| 25mg Eluxadoline + 100mg Eluxadoline | AbbVie | Phase 3 | 77 |
| Eluxadoline + Placebo | AbbVie | Phase 2 | 52 |
| Tegaserod | Novartis | Pre-clinical | 23 |
| DNK333 | Novartis | Phase 2 | 52 |
| SMS995 + Placebo | Novartis | Phase 1 | 33 |
| DNK333 + Placebo | Novartis | Phase 2 | 52 |